Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (550-562), 10.1007/s00259-021-05489-8)

Research output: Contribution to journalComment/debate

Abstract

The article “Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer”, written by Sudipta Roy, Timothy D. Whitehead, Shunqiang Li, Foluso O. Ademuyiwa, Richard L. Wahl, Farrokh Dehdashti, and Kooresh I. Shoghi, was originally published electronically on the publisher’s internet portal on July 30, 2021 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article changed on August 22, 2021 to

Original languageEnglish
Pages (from-to)788
Number of pages1
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume49
Issue number2
DOIs
StatePublished - Jan 2022

Fingerprint

Dive into the research topics of 'Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (550-562), 10.1007/s00259-021-05489-8)'. Together they form a unique fingerprint.

Cite this